Skip to content
Agentic OS
Menu

Intelligence / Healthtech / PMA Approvals / Diasorin, INC.

Approvalsdevice change approved (PMA)27 Aug 2026

Diasorin, INC.

27 Aug 2026: Device change approved (PMA) · LIAISON QuantiFERON-TB Gold Plus; LIAISON XL Control QuantiFERON-TB Gold Plus; LIAISON QuantiFERON-TB Gold Plus II; LIAI. Recorded in the openFDA device PMA data.

View the source record

Decided
27 Aug 2026
Device
LIAISON QuantiFERON-TB Gold Plus; LIAISON XL Control QuantiFERON-TB Gold Plus; LIAISON QuantiFERON-TB Gold Plus II; LIAI
Specialty
Microbiology
Type
Supplement (Normal 180 Day Track)
Reason
Labeling Change - Indications/instructions/shelf life/tradename
Reference
P180047 S043
Location
Stillwater, MN
What this signal means

A PMA approval is a high-risk device launch: reimbursement, distribution, clinical training and sales hires follow.

  1. Cardiovascular leads with 53 of 120, then Pathology (15).
  2. 35 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Diasorin, INC.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.

Start free

Across AOS Research

Other records for Diasorin, INC. in our registers.

Source: openFDA device PMA data, data to 18 Nov 2026. Class III devices approved by FDA: original approvals and supplements that change the device (180-day, panel-track and special tracks). 30-day manufacturing notices are left out. AOS shows what the public record says; it does not verify or endorse the company.